Oak Hill Bio Details Discovery and Development of Rugonersen
09 Sep 2025 //
BUSINESSWIRE
Oak Hill Bio Publishes Rugonersen Phase 1 Study Results
11 Jul 2025 //
BUSINESSWIRE
Oak Hill Bio Licenses Angelman Syndrome Treatment to Roche
15 Apr 2025 //
BUSINESSWIRE
Oak Hill Bio Promotes Josh Distler To Chief Executive Officer
07 Oct 2024 //
BUSINESSWIRE
Oak Hill Bio, Chiesi Enroll First BPD Prevention Phase 2b
17 May 2024 //
PR NEWSWIRE